These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

446 related items for PubMed ID: 37962724

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Clinical benefit, development, innovation, trials, epidemiology, and price for cancer drugs and indications with multiple special FDA designations.
    Michaeli DT, Michaeli T, Albers S, Michaeli JC.
    J Natl Cancer Inst; 2024 Feb 08; 116(2):216-229. PubMed ID: 37824202
    [Abstract] [Full Text] [Related]

  • 3. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E.
    Orphanet J Rare Dis; 2017 Jan 05; 12(1):1. PubMed ID: 28057032
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price.
    Michaeli JC, Michaeli T, Trapani D, Albers S, Dannehl D, Würstlein R, Michaeli DT.
    Breast Cancer; 2024 Nov 05; 31(6):1144-1155. PubMed ID: 39320645
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Iodine-131 Tositumomab: (131)I-anti-B1 antibody, (131)I-tositumomab, anti-CD20 murine monoclonal antibody-I-131, B1, Bexxar, (131)I-anti-B1 antibody, iodine-131 tositumomab, iodine-131 anti-B1 antibody, tositumomab.
    BioDrugs; 2003 Nov 05; 17(4):290-5. PubMed ID: 12899647
    [Abstract] [Full Text] [Related]

  • 9. FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.
    Michaeli T, Jürges H, Michaeli DT.
    BMJ; 2023 May 09; 381():e073242. PubMed ID: 37160306
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Premarket Pivotal Trial End Points and Postmarketing Requirements for FDA Breakthrough Therapies.
    Mooghali M, Wallach JD, Ross JS, Ramachandran R.
    JAMA Netw Open; 2024 Aug 01; 7(8):e2430486. PubMed ID: 39190303
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
    Monge AN, Sigelman DW, Temple RJ, Chahal HS.
    JAMA Netw Open; 2022 Nov 01; 5(11):e2239336. PubMed ID: 36318210
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Analysis of US Food and Drug Administration new drug and biologic approvals, regulatory pathways, and review times, 1980-2022.
    Seoane-Vazquez E, Rodriguez-Monguio R, Powers JH.
    Sci Rep; 2024 Feb 09; 14(1):3325. PubMed ID: 38336899
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.